Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
The DOI matches its Crossref record.
Abstract
The chelator currently used to treat iron (Fe) overload disease, desferrioxamine (DFO), has shown anti-proliferative activity against leukemia and neuroblastoma cells in vitro, in vivo and in clinical trials. Collectively, these studies suggest that Fe-deprivation may be a useful anti-cancer strategy. However, the efficacy of DFO is severely limited due to its poor ability to permeate cell membranes and bind intracellular Fe pools. These limitations have encouraged the development of other Fe chelators that are far more effective than DFO. One group of ligands that have been extensively investigated are those of the pyridoxal isonicotinoyl hydrazone (PIH) class. In this review the marked anti-proliferative effects of the PIH analogs are discussed with reference to their mechanisms of action and structure-activity relationships. In particular, we discuss the activity of a novel group of ligands that are "hybrid" chelators derived from our most effective PIH analogs and thiosemicarbazones. The anti-tumor activity of the PIH analogs and other chelators such as tachpyridine, O-trensox and the desferrithiocin analogs have been well characterized in vitro. However, further studies in animals are critical to evaluate their selective anti-tumor activity and potential as therapeutic agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, pyridoxal isonicotinyl hydrazone (PIH) [1672,1715-1720] is a promising molecule (also proposed in anti-cancer therapy), although it is hydrolysed both in vivo and in vitro [1721].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1719]
Citations
Cites
Still being checked.
Cited by
Redox- and non-redox-metal-induced formation of free radicals and their role in human disease
Valko, M., Jomova, K., Rhodes, C. J., Kuča, K., & Musílek, K. (2016) · Archives of Toxicology · doi:10.1007/s00204-015-1579-5 · Cited by 1,022
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Microbial siderophores and their potential applications: a review
Saha, M., Sarkar, S., Sarkar, B., Sharma, B. K., Bhattacharjee, S., & Tribedi, P. (2016) · Environmental Science and Pollution Research · doi:10.1007/s11356-015-4294-0 · Cited by 819
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Self-citationKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Huang, X. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2003.08.023 · Cited by 444
Yuan, J., Lovejoy, D. B., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-03-0868 · Cited by 381
Self-citationOxidative Stress and Iron Homeostasis: Mechanistic and Health Aspects
Galaris, D., & Pantopoulos, K. (2008) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360701713104 · Cited by 352
Le, N. T. V., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-05-1866 · Cited by 321
Self-citationManagement of oxidative stress and other pathologies in Alzheimer’s disease
Simunkova, M., Alwasel, S. H., Alhazza, I. M., Jomova, K., Kollar, V., Rusko, M., & Valko, M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02538-y · Cited by 303
Ribonucleotide Reductase Inhibitors and Future Drug Design
Shao, J., Zhou, B., Chu, B., & Yen, Y. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906777723949 · Cited by 284
Anticancer Activity of the Antibiotic Clioquinol
Ding, W.-Q., Liu, B., Vaught, J. L., Yamauchi, H., & Lind, S. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3577 · Cited by 248
Synthetic and natural iron chelators: Therapeutic potential and clinical use
Hatcher, H. C., Singh, R. N., Torti, F. M., & Torti, S. V. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.121 · Cited by 242
Bacterial siderophores: diversity, uptake pathways and applications
Schalk, I. J. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01090-6 · Cited by 227
Rose, C., Brechignac, S., Vassilief, D., Pascal, L., Stamatoullas, A., Guerci, A., Larbaa, D., Dreyfus, F., Beyne-Rauzy, O., Chaury, M. P., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.12.004 · Cited by 195
The neglected significance of “antioxidative stress”
Poljsak, B., & Milisav, I. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/480895 · Cited by 177
A review of metal‐catalyzed molecular damage: protection by melatonin
Romero, A., Ramos, E., de Los Ríos, C., Egea, J., del Pino, J., & Reiter, R. J. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12132 · Cited by 174
Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities
Zhang, C., & Zhang, F. (2015) · Protein & Cell · doi:10.1007/s13238-014-0119-z · Cited by 147
Metal ionophores – An emerging class of anticancer drugs
Ding, W., & Lind, S. E. (2009) · IUBMB Life · doi:10.1002/iub.253 · Cited by 155
Iron: a target for the management of Kaposi's sarcoma?
Simonart, T. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-1 · Cited by 134
Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S. (2008) · The FASEB Journal · doi:10.1096/fj.07-8627rev · Cited by 126
Barve, V., Ahmed, F., Adsule, S., Banerjee, S., Kulkarni, S., Katiyar, P., Anson, C. E., Powell, A. K., Padhyé, S., & Sarkar, F. H. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051068y · Cited by 132
Guo, M., Song, L., Jiang, Y., Liu, W., Yu, Y., & Chen, G. (2005) · APOPTOSIS · doi:10.1007/s10495-005-3085-3 · Cited by 142
Chaston, T. B., Watts, R. N., Yuan, J., & Richardson, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0865 · Cited by 120
Self-citationClioquinol targets zinc to lysosomes in human cancer cells
Yu, H., Zhou, Y., Lind, S. E., & Ding, W. (2008) · Biochemical Journal · doi:10.1042/bj20081421 · Cited by 114
Lane, D. J. R., Robinson, S. R., Czerwinska, H., Bishop, G. M., & Lawen, A. (2010) · Biochemical Journal · doi:10.1042/bj20101317 · Cited by 100
Targeting ribonucleotide reductase for cancer therapy
Shao, J., Liu, X., Zhu, L., & Yen, Y. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.840293 · Cited by 92
Bernhardt, P. V., Caldwell, L. M., Chaston, T. B., Chin, P., & Richardson, D. R. (2003) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-003-0486-z · Cited by 96
Self-citationComplexes of Cytotoxic Chelators from the Dipyridyl Ketone Isonicotinoyl Hydrazone (HPKIH) Analogues
Bernhardt, P. V., Mattsson, J., & Richardson, D. R. (2005) · Inorganic Chemistry · doi:10.1021/ic051573l · Cited by 83
Self-citationJones, D. T., Trowbridge, I. S., & Harris, A. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3857 · Cited by 75
“Novel iron chelators that have high permeability, such as desferrithiocin analogues, tachpyridine, O-trensox, pyridoxal isonicotinoyl hydrazone analogues, and Triapine, have antiproliferative effect and cause a marked cell cycle arrest and apoptosis in vitro and in vivo (41, 43, 44).”
Iron: Effect of Overload and Deficiency
Hider, R. C., & Kong, X. (2013) · Metal ions in life sciences · doi:10.1007/978-94-007-7500-8_8 · Cited by 93
Recent advances in cancer treatment by iron chelators
Corcé, V., Gouin, S. G., Renaud, S., Gaboriau, F., & Deniaud, D. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.094 · Cited by 81
Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity
Bernhardt, P. V., Chin, P., Sharpe, P. C., Wang, J.-Y. C., & Richardson, D. R. (2005) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-005-0018-0 · Cited by 67
Self-citationBernhardt, P. V., Wilson, G. J., Sharpe, P. C., Kalinowski, D. S., & Richardson, D. R. (2007) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-007-0300-4 · Cited by 64
Self-citationZinc-binding compounds induce cancer cell death via distinct modes of action
Ding, W., Yu, H., & Lind, S. E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.011 · Cited by 64
The Effect of Lycopene Preexposure on UV‐B‐Irradiated Human Keratinocytes
Ascenso, A., Pedrosa, T., Pinho, S., Pinho, F., Oliveira, J. M. P. F. D., Cabral Marques, H., Oliveira, H., Simões, S., & Santos, C. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8214631 · Cited by 57
The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
Chekmarev, J., Azad, M. G., & Richardson, D. R. (2021) · Cells · doi:10.3390/cells10092382 · Cited by 56
Self-citationIron is not involved in oxidative stress‐mediated cytotoxicity of doxorubicin and bleomycin
Mertlíková‐Kaiserová, H., den Hartog, G. J. M., Šimůnek, T., Schröterová, L., Kvasničková, E., & Bast, A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706930 · Cited by 56
Liu, W., Guo, M., Xu, Y.-B., Li, D., Zhou, Z.-N., Wu, Y.-L., Chen, Z., Kogan, S. C., & Chen, G.-Q. (2006) · Blood · doi:10.1182/blood-2005-03-1278 · Cited by 51
Matoga, D., Szklarzewicz, J., Stadnicka, K. M., & Shongwe, M. S. (2007) · Inorganic Chemistry · doi:10.1021/ic701435x · Cited by 49
Novel Near-Infrared Fluorescent Integrin-Targeted DFO Analogue
Ye, Y., Bloch, S. R., Xu, B. J., & Achilefu, S. (2007) · Bioconjugate Chemistry · doi:10.1021/bc7003022 · Cited by 50
Siderophores for medical applications: Imaging, sensors, and therapeutics
Fan, D., & Fang, Q. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120306 · Cited by 57
Investigation of the stability of aromatic hydrazones in plasma and related biological material
Kovaříková, P., Mrkvičková, Z., & Klimeš, J. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.01.011 · Cited by 44
Melatonin’s role in preventing toxin-related and sepsis-mediated hepatic damage: A review
Zubero, E. E., Alatorre-Jiménez, M. A., López‐Pingarrón, L., Reyes-Gonzales, M. C., Souza, P. A., Cantín-Golet, A., Ruiz-Ruiz, F. J., Tan, D., García, J. J., & Reiter, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.018 · Cited by 46
Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs
Buss, J. L., Neužil, J., & Ponka, P. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.09.044 · Cited by 48
Enterobactin, an iron chelating bacterial siderophore, arrests cancer cell proliferation
Saha, P., Yeoh, B. S., Xiao, X., Golonka, R. M., Kumarasamy, S., & Vijay–Kumar, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.017 · Cited by 41
Schmid, W. F., Zorbas‐Seifried, S., John, R. O., Arion, V. B., Jakupec, M. A., Roller, A., Galanski, M. S., Chiorescu, I., Zorbas, H., & Keppler, B. K. (2007) · Inorganic Chemistry · doi:10.1021/ic070098j · Cited by 39
Lou, J. R., Zhang, X.-X., Zheng, J., & Ding, W. (2010) · PubMed · Cited by 48
Clioquinol Promotes Cancer Cell Toxicity through Tumor Necrosis Factor α Release from Macrophages
Du, T., Filiz, G., Caragounis, A., Crouch, P. J., & White, A. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130377 · Cited by 39
Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition
Zhang, C., Liu, G., & Huang, M. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1302-6 · Cited by 37
Carter, A., Racey, S. N., & Veuger, S. J. (2022) · Applied Sciences · doi:10.3390/app121910161 · Cited by 37
Malaria and iron: history and review
Weinberg, E. D., & Moon, J. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530903178905 · Cited by 42
Angelova, V. T., Vassilev, N. G., Nikolova-Mladenova, B., Vitas, J. S., Malbaša, R. V., Momekov, G., Djukic, M. M., & Saso, L. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1661-4 · Cited by 33
Şalış, O., Bedir, A., Kilinc, V., Alaçam, H., GÜLTEN, S., & Okuyucu, A. (2014) · Cancer Biomarkers · doi:10.3233/cbm-140422 · Cited by 32
Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Merlot, A. M., Kalinowski, D. S., Kovačević, Ž., Jansson, P. J., Sahni, S., Huang, M., Lane, D. J. R., Lok, H. C., & Richardson, D. R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170705120809 · Cited by 31
Self-citationHypercoagulability preceding cancer
Nierodzik, M. L., & Karpatkin, S. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01174.x · Cited by 30
Prodrugs in Photodynamic Anticancer Therapy
Musioł, R., Serda, M., & Polański, J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798194549 · Cited by 29
19F-MRS/1H-MRI dual-function probe for detection of β-galactosidase activity
Yu, J.-X., Kodibagkar, V., Liu, L., Zhang, Z., Magnusson, J., & Liu, Y.-T. (2013) · Chemical Science · doi:10.1039/c3sc21099e · Cited by 18
Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?
Hecel, A., Ostrowska, M., Stokowa‐Sołtys, K., Wątły, J., Dudek, D., Miller, A., Potocki, S., Matera-Witkiewicz, A., Domínguez‐Martín, A., Kozłowski, H., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13090228 · Cited by 26
Lescoat, G., Léonce, S., Pierré, A., Gouffier, L., & Gaboriau, F. (2011) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2011.12.003 · Cited by 26
Jirkovská, A., Karabanovich, G., Kubeš, J., Skalická, V., Melnikova, I., Korábečný, J., Kučera, T., Jirkovský, E., Nováková, L., Piskáčková, H. B., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02157 · Cited by 23
Deng, J., Chen, W., & Deng, H. (2016) · Journal of Fluorescence · doi:10.1007/s10895-016-1892-2 · Cited by 23
Pharmacological activity of DTPA linked to protein-based drug carrier systems
Michaelis, M., Langer, K., Arnold, S., Doerr, H.-W., Kreuter, J., & Cinatl, J. J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.223 · Cited by 21
Rodríguez‐Lucena, D., Gaboriau, F., Rivault, F., Schalk, I. J., Lescoat, G., & Mislin, G. L. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.11.057 · Cited by 18
Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments
Leitch, H. A. (2011) · Drugs · doi:10.2165/11585280-000000000-00000 · Cited by 17
Rehan, M., Barakat, H., Almami, I. S., Qureshi, K. A., & Alsohim, A. S. (2022) · Fermentation · doi:10.3390/fermentation8080346 · Cited by 22
Sarno, F., Papulino, C., Franci, G., Andersen, J. H., Cautain, B., Melardo, C., Altucci, L., & Nebbioso, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01006 · Cited by 16
Clavijo, C. A., Chen, J.-L., Kim, K., Reyland, M. E., & Ann, D. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00425.2006 · Cited by 15
Klener, P., Anděra, L., Klener, P., Nečas, E., & Živný, J. (2006) · Folia Biologica · doi:10.14712/fb2006052040119 · Cited by 19
Le, N. T. V., & Richardson, D. R. (2004) · International Journal of Cancer · doi:10.1002/ijc.20161 · Cited by 14
Self-citationLiu, Y., Jacobs, H. K., & Gopalan, A. S. (2008) · The Journal of Organic Chemistry · doi:10.1021/jo802410u · Cited by 13
Novel trihydroxamate‐containing peptides: Design, synthesis, and metal coordination
Ye, Y., Liu, M., Kao, J. L.-F., & Marshall, G. R. (2006) · Biopolymers · doi:10.1002/bip.20532 · Cited by 14
3-Hydroxy-2-(5-hydroxypentyl)-4H-chromen-4-one: A Bidentate or Tridentate Iron(III) Ligand?
Kong, X., Zhou, T., Neubert, H., Liu, Z. D., & Hider, R. C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050905t · Cited by 11
Hypercoagulability preceding cancer
Zacharski, L. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01178.x · Cited by 11
Effect of a siderophore producer on animal cell apoptosis: a possible role as anti-cancer agent.
Nakouti, I., Sihanonth, P., Palaga, T., & Hobbs, G. (2013) · Liverpool John Moores University · Cited by 11
Iron Therapeutics in Women’s Health: Past, Present, and Future
Mintz, J. A., Mirza, J., Young, E., & Bauckman, K. (2020) · Pharmaceuticals · doi:10.3390/ph13120449 · Cited by 13
Discovering Novel and Diverse Iron-Chelators in Silico
Basu, A., Sohn, Y., Alyan, M., Nechushtai, R., Domb, A. J., & Goldblum, A. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00450 · Cited by 10
Rouge, P., Dassonville‐Klimpt, A., Cézard, C., Boudesocque, S., Ourouda, R., Amant, C., Gaboriau, F., Forfar, I., Guillon, J., Guillon, E., et al. (2012) · ChemPlusChem · doi:10.1002/cplu.201200141 · Cited by 10
Yergeshov, A. A., Zoughaib, M., Ishkaeva, R. A., Savina, I. N., & Abdullin, T. I. (2022) · Gels · doi:10.3390/gels8020118 · Cited by 9
A systematic review on hydrazones their chemistry and biological activities
Khattar, T., Govindaiah, P., Mishra, A., Ansari, M. D. M., & Kaur, P. (2023) · AIP conference proceedings · doi:10.1063/5.0168993 · Cited by 8
Supplémentation en fer : indications, limites et modalités
Arlet, J. B., Pouchot, J., Lasocki, S., Beaumont, C., & Hermine, O. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.04.007 · Cited by 8
Gutiérrez, S. M., Cardona‐Galeano, W., Herrera‐Ramírez, A., & Yepes, A. F. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03358-1 · Cited by 8
Barakat, H., Qureshi, K. A., Alsohim, A. S., & Rehan, M. (2022) · Molecules · doi:10.3390/molecules27134010 · Cited by 9
Chakraborty, S., Mukherjee, P., & Sengupta, R. (2022) · Nitric Oxide · doi:10.1016/j.niox.2022.07.002 · Cited by 8
Mossine, V. V., Kelley, S. P., & Mawhinney, T. P. (2020) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989020003011 · Cited by 6
Ghosh, S. K. (2022) · Fungal biology · doi:10.1007/978-3-030-91650-3_19 · Cited by 5
Kilinc, V., Bedir, A., Okuyucu, A., Şalış, O., Alaçam, H., & GÜLTEN, S. (2014) · Tumor Biology · doi:10.1007/s13277-014-1788-1 · Cited by 3
Mossine, V. V., Kelley, S. P., Waters, J. K., & Mawhinney, T. P. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03028-8 · Cited by 3
Crystal structure of (E)-3-methoxy-N′-(1-(pyridin-2-yl)ethylidene)benzohydrazide, C15H15N3O2
Mossine, V. V., Kelley, S. P., & Mawhinney, T. P. (2020) · Zeitschrift für Kristallographie - New Crystal Structures · doi:10.1515/ncrs-2020-0097 · Cited by 3
Synthesis of gemini triethylene-tetramine bridged bis-tridentate iron(III) chelators
Rodríguez‐Lucena, D., Schalk, I. J., & Mislin, G. L. A. (2011) · Tetrahedron · doi:10.1016/j.tet.2011.01.008 · Cited by 2
Chansiw, N., Pangjit, K., & Tuntiwechapikul, W. (2013) · Vitamins & Minerals · doi:10.4172/vms.1000114 · Cited by 1
THE MOLECULAR MECHANISMS OF IRON AND FERRITIN METABOLISM IN NORMAL AND NEOPLASTIC CELLS
Xu, X. (2008) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 1
Wang, Y., & Liu, H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.02.433682 · Cited by 1
Mutations du gène HFE dans le cancer épithélial de l'ovaire
Medelci, S. (2008) · doi:10.71781/31650
Venous thromboembolism prevention in cancer patients: the search for common antecedents
Zacharski, L. R., & Engman, C. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.13.2117
Journal of Experimental and Clinical Medicine Deneysel ve Klinik Tip Dergisi
Okuyucu, A., Bedir, A., Özmen, Z. C., & Biyokimya, T. D. H. (2012)
Chen, G., Liu, W., Guo, M., Xu, Y., Li, D., Zhou, Z.-N., Wu, Y., Chen, Z., & Kogan, S. C. (2010)
da Silva, E. M. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2017.tde-25102016-150408 · Cited by 2
Metadata
- Authors
- Lovejoy, D., & Richardson, D.
- Affiliations
- Children's Cancer Institute Australia (AU)
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-06-01
- Volume
- 10
- Issue
- 12
- Pages
- 1035-1049
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2002176182
- Cited by
- 98
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 4
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- iron chelators, pyridoxal isonicotinoyl hydrazone, deferoxamine, iron starvation, anticancer agents, antiproliferative activity, leukemia, neuroblastoma, thiosemicarbazones, structure-activity relationship, iron overload
- MeSH terms
- Animals, Antineoplastic Agents, Deferoxamine, Humans, Hydrazones, Iron, Iron Chelating Agents, Neoplasms, Structure-Activity Relationship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.